AEMD
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Aethlon Medical, Inc. (AEMD) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (D+). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B+ (3.7) | B (3.2) | D+ (1.7) | C (2.2) | C+ (2.6) | C+ (2.7) |
| 2026-11-10 | A- (3.9) | B (3.2) | D+ (1.7) | C (2.3) | C+ (2.6) | C+ (2.7) |
| 2026-11-03 | B+ (3.7) | B (3.2) | D+ (1.7) | C (2.2) | C+ (2.7) | C+ (2.7) |
| 2026-10-27 | B+ (3.7) | B (3.2) | D+ (1.7) | C (2.2) | C+ (2.6) | C+ (2.7) |
| 2026-10-20 | B+ (3.7) | B (3.2) | D+ (1.7) | C (2.2) | C+ (2.6) | C+ (2.7) |